• Skip to primary navigation
  • Skip to main content
Engineered Tissue Solutions

Engineered Tissue Solutions

  • Chronic Wound Care
    • Mirragen
    • Clinical Evidence
    • ETS Case Studies
    • Testimonials
  • Surgical Wound Care
    • MirraSurg
    • Clinical Evidence
    • ETS Case Studies
    • Testimonials
  • Science & Technology
  • Provider & Patient Support
    • For Providers
    • For Patients
    • Reimbursement
  • About
    • Contact Us
    • News & Events
    • Careers
    • Testimonials
  • Request Information

Contact Us

O: 573.202.2550 —- F: 573.755.0588

ets.support@heraeus.com

Headquarters

4030 HyPoint North, Rolla, MO 65401 USA

See how we’re transforming wound care.

If you are a provider and would like to receive samples of Mirragen® and/or additional information, please fill out our sample request form. For more information on reimbursement please contact ets.support@heraeus.com.

Request Information

News

Engineered Tissue Solutions Celebrates Publication of Second Randomized Controlled Trial Demonstrating Statistically Significant Outcomes with Mirragen® Bioactive Glass Matrix


Engineered Tissue Solutions and Transdiagen Partner to Pioneer Gene Expression Research in Chronic Wound Healing


New Whitepapter: Addressing the Burden of Complex Surgical Wounds with MirraSurg (WOUNDS)

ETS Awarded Technology Breakthrough Designation for Mirragen® Bioactive Glass with Premier, Inc.

ETS Named 2024 MedTech Outlook Wound Care Solution Company of the Year

Dr. Ralph Napolitano’s Work Using Bioactive Glass Technology Wins SAWC Fall 2024 People’s Choice Award

The People Have Spoken: Mercy’s Use of Bioactive Glass Technology Recognized at SAWC Fall 2024

Engineered Tissue Solutions Announces AJ Ford as New CEO

ETS Receives Innovative Technology Contract from Vizient for Mirragen® Advanced Wound Matrix

Celebrating International Women’s Day: Meet Daniella DeMichele, VP of Sales at Engineered Tissue Solutions (ETS)

Heraeus expands and diversifies its medical technology portfolio with acquisition of Mo-Sci Corporation and ETS Technology Holdings

Learn More

ETS On The Frank & Lizzie Show

Events

Webinar: Second Landmark RCT Evaluating Mirragen in Diabetic Foot Ulcers | November 13, 2025

Join the leading minds in wound care for a webinar on a recently published RCT demonstrating Mirragen’s impact on non-healing DFUs.

WoundCon: A Case-Based Approach to Managing Complex Chronic Wounds with Borate-Based Bioactive Glass Fiber

Learn from the physicians who use bioactive glass technology.

Wound Masterclass: Destination Closure for Wounds

Gain CME Credits and Learn How Bioactive Glass Technology is Transforming Wound Care


Masterclass
Webinar
Second Landmark RCT Evaluating Mirragen in Diabetic Foot Ulcers | November 13, 2025

Join the leading minds in wound care for a webinar on a recently published RCT demonstrating Mirragen's impact on non-healing DFUs.

Learn More
Premier
News Release
Engineered Tissue Solutions Celebrates Publication of Second Randomized Controlled Trial Demonstrating Statistically Significant Outcomes with Mirragen® Bioactive Glass Matrix

The 148-patient randomized controlled trial (RCT) shows Mirragen® to be more effective than standard of care alone in the management of diabetic foot ulcers (DFUs).

Learn More
Ohio
News Release
Engineered Tissue Solutions and Transdiagen Partner to Pioneer Gene Expression Research in Chronic Wound Healing

Partnership to assess gene expression changes in chronic wounds treated with Mirragen®, marking the first time any skin substitute has undergone such a genomic-level evaluation in a chronic wound environment.

Learn More
Premier
News Release
ETS Awarded Technology Breakthrough Designation for Mirragen® Bioactive Glass with Premier, Inc.

Premier offers Breakthrough Technology designations to innovations that offer a major advantage in terms of patient safety, clinical outcomes and operational efficiencies.

Learn More
Frank Lizzie
News & Events
ETS Featured on The Frank & Lizzie Show

Dr. Steven Jung, ETS Chief Technology Officer, and AJ Ford, ETS CEO, sat down on the show to discuss the many benefits of using Mirragen® when treating the most challenging wounds.

Watch
Vizient
News
ETS Receives Innovative Technology Contract from Vizient for Mirragen Advanced Wound Matrix
Learn More
WoundCon
Event
WoundCon: A Case-Based Approach to Managing Complex Chronic Wounds with Borate-Based Bioactive Glass Fiber

Explore the role of synthetics in wound healing and their importance in creating an optimal healing environment.

Learn More
Award
News
ETS Named 2024 MedTech Outlook Wound Care Solution Company of the Year

Reimagining Healing with the Power of Mirragen's Bioactive Glass Technology

Learn More
previous arrow
next arrow

Learn how ETS is transforming wound care.

Access Literature
  • Request Information
  • Contact Us
  • Careers
  • LinkedIn
  • Facebook
  • Instagram
  • Disclaimer
  • Privacy
  • Terms & Conditions
  • Patents

MIRRAGEN® is a registered trademark of ETS Tech Holdings, LLC. | © ETS Wound Care